Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
On World TB Day 2017, MSF and civil society sent an open letter to Otsuka urging for increased access to delamanid in South Africa. Download the letter
Last updated 24 March 2017
MSF statement at Human Rights Council panel discussion on the UN Secretary-General's High-Level Panel on Access to Medicines
MSF enthusiastically welcomes the report from the UN Secretary-General’s High-Level Panel on Access to Medicines, which puts forth actionable recommendations to help overcome the challenges that our medical teams have faced for decades – being left essentially empty-handed when the medicines, vaccines and diagnostics we need for patients don’t exist, or are too expensive.
MSF Access Campaign's letter to all 16 countries negotiating Regional Comprehensive Economic Partnership (RCEP) sharing serious concerns over proposed provisions in the RCEP investment chapter that threaten to restrict access to affordable medicines for millions of people.
Last updated 24 February 2017
Letter to Gilead Sciences requesting expansion of not-for-profit price of key drug L-AMB to include indication of cryptococcal meningitis
16 February 2017 Open letter to request Gilead Sciences to expand its not-for-profit price of L-AMB to include the indication of cryptococcal meningitis for all low- and middle-income countries, where the disease burden is greatest, such that people with HIV may access the best possible treatment with fewer side effects, regardless of where they live.
Last updated 16 February 2017
Submitted February 9, 2017. MSF to deliver testimony on 8 March 2017 to the Office of the US Trade Representative for the US 2017 Special 301 Report hearing. Doctors Without Borders/Médecins Sans Frontières (MSF) would like to offer testimony in the 2017 United States Trade Representative (USTR) Special 301 Review.
Last updated 9 February 2017
Letter from Health groups calling on Ministry of Health, India to make anti TB drug named Delamanid available under Revised National Tuberculosis Control Program. Download PDF of letter
Last updated 27 January 2017
Speaker: Nathalie Ernoult/Juliette Puret Médecins Sans Frontières is concerned by the slow progress towards the GVAP targets, with only a one percent increase in global vaccination coverage since 2010. MSF acknowledges the recommendations of the SAGE, but we feel the following four issues warrant immediate attention:
Last updated 26 January 2017
140th WHO EB - Intervention - Agenda Item 8.3 Addressing the global shortages of medicines and vaccines
Speaker: Rachael Hore Shortages and stock outs of medicines, vaccines and diagnostics continue to be a challenge that MSF encounters each day in our work. Shortages and stock outs have an unacceptable impact on patients, as their consequences can lead to poor health outcomes.
Doctors Without Borders/ Médecins Sans Frontières (MSF) comments to the Department of Defense notice of intent to grant an exclusive license of U.S. government-owned patents on a Zika vaccine candidate
January 23, 2017
Last updated 25 January 2017
Speaker: Katy Athersuch MSF witnesses, first-hand, the emergence of antimicrobial resistance in a wide range of our operational contexts. MSF was invited to speak at the UN High Level Meeting on Antimicrobial resistance last year, and we welcome the commitments made by Member States that reaffirm the strategies in the 2015 WHO AMR Global Action Plan.
Last updated 25 January 2017